Paul Gard

Prof. Paul Gard


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2002 in European Journal of Pharmacology
Verified
Journal Article
Closed access
PGPaul Gard
Paul Gard

3 December 2008 in BMC Neuroscience
Verified
Journal Article
Open access
PDF file
PGPaul Gard
Paul Gard
Angiotensin IV is a derivative of the potent vasoconstrictor angiotensin II and it has been shown to enhance acquisition, consolidation and recall in animal models of learning and memory when administered centrally or peripherally. Whether changes in angiotensin IV activity underlie the cognitive effects of those cardiovascular drugs designed to disrupt the peripheral renin-angiotensin system in humans remains undetermined, but angiotensin IV appears to be a worthy candidate for consideration in drug development programmes. The mechanism of action of angiotensin IV is still debated, although its AT4 receptor has been convincingly identified as being insulin-regulated amino peptidase, which is also known as oxytocinase and placental leucine aminopeptidase. It is speculated that angiotensin IV may interact with insulin-regulated amino peptidase to enhance neuronal glucose uptake, prevent metabolism of other neuroactive peptides, induce changes in extracellular matrix molecules, or induce release of acetylcholine and/or dopamine. All of these things may be responsible for the beneficial effects on cognition, but none of them are yet proven. Importantly, strain differences in murine responses to angiotensin IV suggest that some individuals may benefit from drugs targeted to the AT4 receptor whilst others may be refractory. At present it thus appears that those individuals with the poorest baseline cognition may receive greatest benefit, but possible genetic differences in responses to angiotensin IV cannot be ruled-out.

1 May 2001 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Closed access
PGPaul Gard
Paul Gard
SHSamantha J Haigh
Samantha J Haigh
PCPiero T Cambursano
Piero T Cambursano
CWClaire A Warrington
Claire A Warrington

10 January 2004 in Expert Review of Neurotherapeutics
Verified
Journal Article
Closed access
PGPaul Gard
Paul Gard
JRJennifer M Rusted
Jennifer M Rusted
This review describes the features of Alzheimer's disease and discusses the evidence that antihypertensive therapies may be beneficial in its treatment and prevention. Drugs acting via the renin-angiotensin system are considered and it is suggested that these drugs may produce their effects via mechanisms other than by their antihypertensive actions. Using evidence from animal studies, the role of angiotensin as a neurotransmitter and its involvement in the control of normal cognitive function is described. Studies of angiotensin and human cognition are reviewed along with studies investigating the possible link between disorders of the system, either inherited or acquired, and the symptoms of Alzheimer's disease. The therapeutic potential of screening for markers of renin-angiotensin abnormality for the prediction of Alzheimer's disease is considered, as is the potential use of agents known to influence the renin-angiotensin system in the treatment or prevention of the disease.


1 May 2012 in European Journal of Pharmacology
Verified
Journal Article
Closed access
PGPaul Gard
Paul Gard
CNCathy Naylor
Cathy Naylor
SASofiya Ali
Sofiya Ali
CPClare Partington
Clare Partington